The future of targeted therapies for brain metastases.
暂无分享,去创建一个
[1] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Y. Yamada,et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.
[3] G. Nagaraj,et al. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer , 2015, Breast Cancer Research and Treatment.
[4] Sean Khozin,et al. FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[5] Caicun Zhou,et al. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. , 2015, Clinical lung cancer.
[6] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[7] R. Weil,et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.
[8] J. Pichler,et al. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases , 2015, Neuropathology and applied neurobiology.
[9] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[10] S. Margolin,et al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Ricken,et al. Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases , 2015, Histopathology.
[12] J. Hainfellner,et al. Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer , 2014, Histopathology.
[13] K. Blackwell,et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] P. Brastianos,et al. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues , 2014, Acta Neuropathologica.
[15] A. Shaw,et al. 1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Ruey-min Lee,et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.
[17] B. Dréno,et al. Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib , 2014, Journal of Neuro-Oncology.
[18] J. O’Shaughnessy,et al. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. , 2014, Lung cancer.
[19] D. Kondziolka,et al. It is time to reevaluate the management of patients with brain metastases. , 2014, Neurosurgery.
[20] A. Ferro,et al. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series. , 2014, Clinical genitourinary cancer.
[21] Michael Thomas,et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. , 2014 .
[22] P. Ascierto,et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.
[23] M. Preusser,et al. ROS1 translocations and amplifications in lung cancer brain metastases , 2014, Journal of Neuro-Oncology.
[24] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[25] W. Wick,et al. Microenvironmental Clues for Glioma Immunotherapy , 2014, Current Neurology and Neuroscience Reports.
[26] H. Heinzl,et al. Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases , 2014, Strahlentherapie und Onkologie.
[27] A. Ravaud,et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. , 2014, Clinical genitourinary cancer.
[28] R. Dummer,et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.
[29] C. Rödel,et al. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib , 2014, Strahlentherapie und Onkologie.
[30] P. Sharma,et al. PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.
[31] Katherine W Ferrara,et al. Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[32] N. Lin,et al. CNS Metastases in Breast Cancer: Old Challenge, New Frontiers , 2013, Clinical Cancer Research.
[33] Yasuyoshi Watanabe,et al. 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer , 2013, The Journal of Nuclear Medicine.
[34] Myles A Brown,et al. PET imaging of oestrogen receptors in patients with breast cancer. , 2013, The Lancet. Oncology.
[35] T. Choueiri,et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. , 2013, Clinical genitourinary cancer.
[36] Susan M. Chang,et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. , 2013, The Lancet. Oncology.
[37] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[38] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[39] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[40] Erin M. Olson,et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] C. Bokemeyer,et al. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. , 2013, Lung cancer.
[42] C. Marosi,et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. , 2013, Lung cancer.
[43] Meihua Wang,et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. , 2013, International journal of radiation oncology, biology, physics.
[44] J. Pichler,et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical and Experimental Metastasis.
[45] S. Vaidhyanathan,et al. Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[46] J. Brugarolas,et al. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] R. Gelber,et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). , 2013, The Lancet. Oncology.
[48] Joe Y. Chang,et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Daniela Prayer,et al. Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times , 2013, PloS one.
[50] Sacha Gnjatic,et al. The abscopal effect associated with a systemic anti-melanoma immune response. , 2013, International journal of radiation oncology, biology, physics.
[51] M. Preusser,et al. Optimal Management of Brain Metastases from Breast Cancer , 2013, CNS Drugs.
[52] D. Schadendorf,et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. , 2012, European journal of cancer.
[53] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[54] B. Neyns,et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. , 2012, European journal of cancer.
[55] O. Chinot,et al. Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.
[56] A. Hauschild,et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[57] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[58] C. Marosi,et al. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors , 2012, British Journal of Cancer.
[59] A. Niemierko,et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype , 2012, Breast Cancer Research and Treatment.
[60] E. Winer,et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Wolchok. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] R. Dziadziuszko,et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain , 2012, Breast Cancer Research.
[63] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[64] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[65] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[66] G. Ceresoli. Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. , 2012, Current cancer drug targets.
[67] D. Fortin. The blood-brain barrier: its influence in the treatment of brain tumors metastases. , 2012, Current cancer drug targets.
[68] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Pichler,et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases , 2012, Acta Neuropathologica.
[70] M. Jamal-Hanjani,et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Metastatic to the Brain , 2011, Clinical Cancer Research.
[71] M. Gnant,et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases , 2011, British Journal of Cancer.
[72] H. Rugo,et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.
[73] P. Steeg,et al. In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis: A Complementary Magnetic Resonance Imaging Approach , 2011, Investigative radiology.
[74] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[75] P. Hwu,et al. Prognostic factors for survival in melanoma patients with brain metastases , 2011, Cancer.
[76] C. Porta,et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases , 2011, Cancer.
[77] L. Sequist,et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. , 2010, Neuro-oncology.
[78] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[79] B. Yeap,et al. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib , 2010, Clinical Cancer Research.
[80] P. Steeg,et al. Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.
[81] K. Harmankaya,et al. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma , 2010, BMC Cancer.
[82] C. Szczylik,et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[84] Sang-We Kim,et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. , 2009, Lung cancer.
[85] J. Shih,et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] G. Steger,et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.
[87] E. Gerstner,et al. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] E. Winer,et al. Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.
[89] N. Harbeck,et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.
[90] P. Cornu,et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force , 2006, European journal of neurology.
[91] R. Weil,et al. Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.
[92] J. Posner,et al. Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.
[93] M. Dewhirst,et al. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. , 2005, AJR. American journal of roentgenology.
[94] E. Winer,et al. CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] Jill S Barnholtz-Sloan,et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] F. Cappuzzo,et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] Marco van Vulpen,et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). , 2002, Oncology reports.
[98] A. Twijnstra,et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.
[99] H. Hansen,et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] L. Hollier,et al. Review of 'It Is Time to Reevaluate the Management of Patients With Brain Metastases' by Kondziolka D, Kalkanis SN, Mehta MP, Ahluwalia M, Loeffler JS in Neurosurgery 75: 1–9, 2014 , 2015 .
[101] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[102] D. Cahill,et al. Systemic Therapy of Brain Metastases , 2014, Current Neurology and Neuroscience Reports.
[103] W. Berger,et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. , 2014, Lung cancer.
[104] D. Kondziolka,et al. The accuracy of predicting survival in individual patients with cancer. , 2014, Journal of neurosurgery.
[105] M. Preusser,et al. Breast cancer brain metastases responding to primary systemic therapy with T-DM1 , 2013, Journal of Neuro-Oncology.
[106] M. Campone,et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.
[107] Jochen Herms,et al. Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.
[108] V. Perry,et al. What is the blood-brain barrier (not)? , 2007, Trends in immunology.
[109] T. Yoshimine,et al. Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats , 2005, Acta Neurochirurgica.